This interpretation is supported by the finding that inhibition of Janus kinase activity by ruxolitinib starting at the time point of infection completely reversed the antiviral activity elicited by IFN-γ against ΔM27-MCMV, despite a 2-day-long IFN preincubation period (Fig. 3B). The gene discussed is IFNG; the disease is infection.